Anti-PD-1/PD-L1 treatment has displayed a wide spectrum of antitumor activity across various tumors, and several anti-PD-1/PD-L1 agents have demonstrated clinical efficacy and manageable tolerance in patients with NSCLC. Here, PDCD1 is linked to non-small cell lung carcinoma.